solute carrier family 25 member 1Genealiases: CIC · CMS23 · CTP · D2L2AD · SEA · SLC20A3
Q-omics provides the consensus-scored SLC25A1 profile across patient tissues and cancer cell-line models. SLC25A1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SLC25A1 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, SLC25A1 protein abundance shows 20,821 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, BLCA, and LSCC as cancer lineages where SLC25A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC25A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC25A1 survival associations across molecular data types. SLC25A1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC25A1 RNA expression–survival associations across cancer types. High SLC25A1 expression shows unfavorable associations in ACC, HNSC, LAML and LUAD, but favorable associations in SCLC and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SLC25A1 RNA expression.
This table summarizes SLC25A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC25A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC25A1 shows lower tumor expression in THCA and higher tumor expression in BLCA, KIRC, HNSC, LUSC and LIHC. The BLCA box plot shows higher SLC25A1 RNA expression in tumor versus normal tissue (log2 FC = +0.871, t-test p < 0.001).
This table shows molecular features associated with SLC25A1 in patient tissues and cancer cell lines. In patient samples, SLC25A1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC25A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
